Cell-Free DNA Bisulfite Sequencing Reveals Epithelial–Mesenchymal Transition Signatures for Breast Cancer
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26178723 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Minsun Stacey Jeon und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center for Epigenetics and Disease Prevention, Institute of Biosciences & Technology, Texas A&M Health Science Center, Houston, TX 77030, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Epithelial-Mesenchymal Transition, Cell-Free Nucleic Acids. Die Arbeit nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Texas A&M University, Texas A&M University Presidential Clinical Research Partnership program.
Abstract (Originalsprache)
Cell-free DNA (cfDNA), shed by malignant tumor cells into extracellular fluid, provides valuable epigenetic information indicative of cancer status. Nipple aspirate fluid (NAF), a noninvasive liquid biopsy from at-risk women, contains nucleic acid and protein biomarkers from adjacent cancer cells, showing promise for breast cancer (BrC) detection. However, despite its potential, the application of cfDNA in NAF for BrC screening is still underexplored. Here, we report a proof-of-concept study for using cfDNA bisulfite sequencing (cfBS) to assess tumor DNA methylation signatures from NAF samples. For four healthy individuals and three BrC patients, cfBS achieved greater than 20× sequencing depth with an average coverage of 26.5× on the genome. A total of 7471 differentially methylated regions were identified, with significant hypermethylation in BrC samples compared to healthy controls. Gene set enrichment analysis indicated that the differentially methylated genes (DMGs) were significantly associated with epithelial–mesenchymal transition (EMT). By developing a novel EMT scoring metric, we found that BrC samples had more of a mesenchymal phenotype than samples from healthy individuals. CDH1, WNT2, and TRIM29 were hypermethylated near the promoter region, while COL5A2 was hypermethylated in the coding region. The DNA methylation and EMT changes were validated through The Cancer Genome Atlas Breast Invasive Carcinoma study, which confirmed that DMGs were associated with gene expression change and that our methylation-based EMT score reliably distinguished tumors from healthy controls. Our findings support the utilization of the NAF cfDNA cfBS methylation profile for noninvasive BrC screening and pave the way for enhanced early detection of this disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Epigenetics and Disease Prevention, Institute of Biosciences & Technology, Texas A&M Health Science Center, Houston, TX 77030, USA.
- Rigor and Reproducibility Core, Institute of Biosciences & Technology, Texas A&M Health Science Center, Houston, TX 77030, USA.
- Department of Nutrition, Texas A&M University, College Station, TX 77843, USA.
- National Cancer Institute, Division of Cancer Prevention, Rockville, MD 20850, USA.
Förderung
- Texas A&M University
- Texas A&M University Presidential Clinical Research Partnership program
Zitieren
APA
Jeon, M. S., Ding, Z., Pei, C., Li, J., Xie, L., Sauter, E., & Zhang, K. K. (2025). Cell-Free DNA Bisulfite Sequencing Reveals Epithelial–Mesenchymal Transition Signatures for Breast Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26178723
Vancouver
Jeon MS, Ding Z, Pei C, Li J, Xie L, Sauter E, et al. Cell-Free DNA Bisulfite Sequencing Reveals Epithelial–Mesenchymal Transition Signatures for Breast Cancer. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26178723
BibTeX
@article{Jeon2025,
author = {Jeon, Minsun Stacey and Ding, Zehuan and Pei, Casey and Li, Jing and Xie, Linglin and Sauter, Edward and Zhang, Ke Kurt},
title = {Cell-Free DNA Bisulfite Sequencing Reveals Epithelial–Mesenchymal Transition Signatures for Breast Cancer},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26178723}
}
EUVIMED